Lyell Immunopharma, Inc.
LYEL· Nasdaq
LYELLyell Immunopharma, Inc.
Filed May 4, 2023 · 10-Q · 34 days after period end · 0001628280-23-015765
| Metric | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|
| Revenue | $65.00K | $553.00K | $2.45M |
| Net Income | -$66.96M | -$68.14M | -$55.04M |
| EPS Diluted | -$0.27 | -$0.28 | -$3.19 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lyell Immunopharma, Inc. · CIK 1806952 · Engraved from SEC EDGAR
ended Mar 31, 2023 · filed May 4, 2023 · 34 d after period end
